Summarizing recent outcomes from the CATT, IVAN, VIEW, HARBOR, and MANTA studies, Dr. Peter Kaiser explains why clinicians can interpret data from these noninferiority trials to substantiate their preference for bevacizumab, ranibizumab, or aflibercept to treat patients with neovascular AMD.